Literature DB >> 33411109

Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia.

Gregory R Mullen1, Steven A Kaplan2.   

Abstract

PURPOSE OF REVIEW: To review the efficacy and safety of mirabegron in men with overactive bladder (OAB) and benign prostatic hyperplasia (BPH). RECENT
FINDINGS: Numerous studies have shown mirabegron to be efficacious and safe in treating symptoms of OAB. More recent studies evaluating the use of mirabegron in men with OAB and BPH have also shown the medication to be effective with few adverse side effects when used as monotherapy or in combination therapy. Mirabegron is an effective and safe treatment for men with OAB and BPH.

Entities:  

Keywords:  Lower urinary tract symptoms; Mirabegron; Overactive; Prostatic hyperplasia; Urinary bladder

Mesh:

Substances:

Year:  2021        PMID: 33411109     DOI: 10.1007/s11934-020-01017-7

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  28 in total

Review 1.  Incontinence in the elderly, 'normal' ageing, or unaddressed pathology?

Authors:  William Gibson; Adrian Wagg
Journal:  Nat Rev Urol       Date:  2017-04-11       Impact factor: 14.432

2.  Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.

Authors:  Christopher R Chapple; Jameel Nazir; Zalmai Hakimi; Sally Bowditch; Francis Fatoye; Florent Guelfucci; Amine Khemiri; Emad Siddiqui; Adrian Wagg
Journal:  Eur Urol       Date:  2017-02-11       Impact factor: 20.096

Review 3.  The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction.

Authors:  Carlos D'Ancona; Bernard Haylen; Matthias Oelke; Luis Abranches-Monteiro; Edwin Arnold; Howard Goldman; Rizwan Hamid; Yukio Homma; Tom Marcelissen; Kevin Rademakers; Alexis Schizas; Ajay Singla; Irela Soto; Vincent Tse; Stefan de Wachter; Sender Herschorn
Journal:  Neurourol Urodyn       Date:  2019-01-25       Impact factor: 2.696

Review 4.  The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates.

Authors:  Kathryn Brigham Egan
Journal:  Urol Clin North Am       Date:  2016-08       Impact factor: 2.241

5.  Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction.

Authors:  Debra E Irwin; Zoe S Kopp; Barnabie Agatep; Ian Milsom; Paul Abrams
Journal:  BJU Int       Date:  2011-01-13       Impact factor: 5.588

Review 6.  Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review.

Authors:  S A Kaplan; C G Roehrborn; P Abrams; C R Chapple; T Bavendam; Z Guan
Journal:  Int J Clin Pract       Date:  2011-01-07       Impact factor: 2.503

7.  Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder.

Authors:  Debra E Irwin; Ian Milsom; Zoe Kopp; Paul Abrams; Walter Artibani; Sender Herschorn
Journal:  Eur Urol       Date:  2009-03-03       Impact factor: 20.096

8.  Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3 -adrenoceptor activation and α1 -adrenoceptor blockade.

Authors:  E C Alexandre; L R Kiguti; F B Calmasini; F H Silva; K P da Silva; R Ferreira; C A Ribeiro; F Z Mónica; A S Pupo; E Antunes
Journal:  Br J Pharmacol       Date:  2016-01-15       Impact factor: 8.739

9.  Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019.

Authors:  Deborah J Lightner; Alexander Gomelsky; Lesley Souter; Sandip P Vasavada
Journal:  J Urol       Date:  2019-08-08       Impact factor: 7.450

10.  What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women.

Authors:  Arnav Agarwal; Leyla N Eryuzlu; Rufus Cartwright; Kristian Thorlund; Teuvo L J Tammela; Gordon H Guyatt; Anssi Auvinen; Kari A O Tikkinen
Journal:  Eur Urol       Date:  2014-01-24       Impact factor: 20.096

View more
  1 in total

1.  Efficacy of Combination Treatment with Tadalafil and Mirabegron in Patients with Benign Prostatic Hyperplasia Who Presented with Persistent Storage Symptoms After Tadalafil Monotreatment: A Prospective, Multicenter, Open-Labeled Study.

Authors:  Masashi Honda; Yusuke Kimura; Shogo Teraoka; Bunya Kawamoto; Shuichi Morizane; Katsuya Hikita; Atsushi Takenaka
Journal:  Yonago Acta Med       Date:  2022-08-04       Impact factor: 1.371

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.